SEPARATION AND ASSAY OF FOUR ANTIHISTAMINE DRUGS DIPHENHYDRAMINE, CHLORPHENIRAMINE, CYPROHEPTADINE AND FEXOFENADINE IN PHARMACEUTICAL FORMS BY A SINGLE HPLC METHOD

HANAN SHASHOa, AMIR ALHAJ SAKURb, SALEH TREFIa*

aQuality Control and Pharmaceutical Chemistry Department, bAnalytical Chemistry Department-University of Aleppo-Syrian Arab Republic
Email: trefi76@yahoo.fr

Received: 17 Jan 2018 Revised and Accepted: 05 Mar 2018

ABSTRACT

Objective: The objective of this study was to develop and validate a single HPLC method, in order to separate and assay four antihistamine drugs diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine in pharmaceutical forms. This method was a practical additional choice in quality control laboratories.

Methods: The chromatographic conditions comprised of a classical C18-type stationary phase (150 × 4.6 mm, 5μ), with a mobile phase consisting of, 2.5g of sodium octane sulfonic acid in a mixture of 500 ml of deionized water and 500 ml of acetonitrile, and apparent pH of 2.0 was adjusted with phosphoric acid. The flow rate was 1 ml/min; the detection wavelengths were at 220 nm, 230 nm, 265 nm and 254 nm for diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine respectively. The temperature was ambient temperature.

Results: The method was validated for linearity with correlation coefficients very close to one, the accuracy with mean recovery values between 95.0-105.0%, precision with relative standard deviations of the calculated concentrations less than 5.0% and specificity in the presence of degradation products. Then it was used successfully to separate a mixture of them and to assay these drugs in pharmaceutical forms purchased from Syria.

Conclusion: The results presented in this paper showed that the developed method was simple and applicable, for the separation and determination of the four drugs in their pharmaceutical forms.

Keywords: HPLC, Diphenhydramine, Chlorpheniramine, Cyproheptadine, Fexofenadine

INTRODUCTION

The simple diphenyl derivative diphenhydramine was the first clinically useful member of the ethanolamine series and serves as the prototype. In addition, to antihistaminic action, it is antiemetic, Antitussive, and has sedative properties. It is used in over-the-counter (OTC) sleep-aid products. The propylamine antihistamines are characterized structurally by an sp3 or sp2 carbon, connecting atom with a carbon chain of two additional carbons linking the key tertiary amino, and diaryl pharmacophore moieties. Those propylamines with a saturated carbon connecting moiety are commonly referred to as the pheniramine. Chlorpheniramine was chosen from this group in our study. The dibenzocycloheptene and dibenzocycloheptene antihistamines may be regarded as phenothiazine analogues in which the sulfur atom has been replaced by an isosteric vinyl group cyproheptadine. Cyproheptadine possesses both antihistamine and antiserotonin activity and is used as an antipruritic agent. Sedation is the most prominent side effect, and this is usually brief disappearing after 3 or 4 d of treatment.

Fexofenadine is a primary oxidative metabolite of terfenadine. Terfenadine was developed during a search for new butyrophenone antipsychotic drugs, as evidenced by the presence of the N-phenylbutanol substituent. Fexofenadine is a second-generation antihistamine, it is selective peripheral H1-receptor blocker that, like produces no clinically significant anticholinergic effects or α1-adrenergic receptor blockade at therapeutic doses. No sedative or another central nervous system (CNS) effects have been reported for this drug. (fig. 1)[1].

Fig. 1: Chemical structures of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine [2]
The recommended analytical methods of analyzing diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine and their related substances as raw materials by the British Pharmacopoeia is HPLC, with different conditions, especially the mobile phases, the used columns and other experimental parameters [2].

Other chromatographic methods for analyzing diphenhydramine in formulations, were reported in the bibliography [3-6].

There were also many chromatographic methods, for determining chlorpheniramine in pharmaceuticals, in the bibliography [7-10].

Several analytical methods, such as liquid chromatography have been reported for the determination of cyproheptadine in pharmaceutical formulations [11-13].

There were also many chromatographic methods for assaying fexofenadine in formulations, which have been reported in the bibliography [13-17].

Other antihistamine drugs, such as brompheniramine maleate was estimated by HPLC [18].

The previous HPLC methods used different mobile phases with different parameters. The majority of these methods used a classical elution with buffers. For this reason, we decided to propose a single ion pair HPLC method. This proposed method may be applied to the four drugs with some advantages. The use of octane sulfonic acid in the mobile phase, instead of buffers improves its flowability through the HPLC chain and reduce problems of precipitation of salts on the electrovans, arising from the use of buffers. This technic of elution using a surfactant such as an octane sulfonic acid diminish the pressure applied on the column.

In addition, we must update the analytical methods in a regular manner in quality control laboratories, in order to choose the best one. Therefore, the objective of this work was to develop and validate an additional single HPLC method, for the assay of four antihistamine drugs diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine in pharmaceutical forms.

MATERIALS AND METHODS

Chemicals and reagents

Working standards of diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine were gifted by Ibn-Alhaytham Industries, Aleppo-Syria. The commercial drugs (brand name- kartastamine [diphenhydramine 25 mg Alshahbaa Industries], beloramine (chlorpheniramine 4 mg Mediotech Industries), cyproheptadine (cyproheptadine 4 mg Asia for pharmaceutical industries) and fexofenadine (fexofenadine 120 mg Ibn Alhaytham Industries) were purchased from Syria; one commercial formulation (carton) of each was analyzed for each active pharmaceutical ingredient. All samples, as received, were stored in the dark at ambient temperature and humidity. They were all analyzed within expiry dates. All the other used reagents were of HPLC grade: acetonitrile (PROL ABO), phosphoric acid (MERCK), sodium octane sulfonic acid (TEDIA), Deionized Water for HPLC and syringe filters 0.45 µm.

Instrumentation

The HPLC instrument used was an Agilent 1260 infinity, equipped with a UV detector. The pH meter used was from Crison.

Reference solutions preparation

A precise quantity of the working standards was accurately weighed, then dissolved in a sufficient volume of deionized water to obtain the starting standard solutions: diphenhydramine 0.4 mg/ml, chlorpheniramine 0.4 mg/ml, cyproheptadine 0.4 mg/ml and fexofenadine 0.4 mg/ml. These starting standard solutions were used for the preparation of the linearity solutions.

Method development and optimization of chromatographic conditions

Selection of detection wavelength

The utilized detection wavelengths were at 220 nm, 230 nm, 265 nm and 254 nm for diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine respectively.

Column selection

An Agilent HC-C18 (octadecylsilane) reversed phase column, 150 x 4.6 mm 5-Micron was utilized.

Mobile phase preparation

The mobile phase consisting of 2.5g of sodium octane sulfonic acid, in a mixture of 500 ml of deionized water and 500 ml of acetonitrile, and apparent pH of 2.0 was adjusted with phosphoric acid.

Formulation solutions preparation

Twenty tablets of kartastamine (diphenhydramine 25 mg Alshahbaa Industries), were crushed and powdered, then a quantity of the powder containing 25 mg diphenhydramine was transferred into a 1000 ml volumetric flask containing deionized water, the content was dispersed under magnetic stirring during 20 min and sonicated for 10 min, until the active pharmaceutical ingredient was well dissolved (C=0.025 mg/ml).

Twenty tablets of beloramine (chlorpheniramine 4 mg Mediotech Industries) were crushed and powdered, then a quantity of the powder containing 8 mg diphenhydramine was transferred into a 100 ml volumetric flask containing deionized water, the content was dispersed under magnetic stirring during 20 min and sonicated for 10 min, until the active pharmaceutical ingredient was well dissolved (C=0.08 mg/ml).

Twenty tablets of cyproheptadine (cyproheptadine 4 mg Asia for pharmaceutical industries) were crushed and powdered, then a quantity of the powder containing 8 mg diphenhydramine was transferred into a 100 ml volumetric flask containing deionized water, the content was dispersed under magnetic stirring during 20 min and sonicated for 10 min, until the active pharmaceutical ingredient was well dissolved (C=0.08 mg/ml).

Degraded starting solutions

The starting standard solutions prepared as mentioned above were standing at room temperature and sunlight for 60 d. Then, they were analyzed for specificity tests demonstration.

Analytical method validation

Method validation was performed under a variety of the international conference on harmonization (ICH) recommended test conditions [19].

RESULTS AND DISCUSSION

HPLC analysis

The chromatographic conditions comprised of a C18 reversed phase column, 150 x 4.6 mm 5-Micron, with a mobile phase consisting of 2.5g of sodium octane sulfonic acid in a mixture of 500 ml of deionized water and 500 ml of acetonitrile, and apparent pH of 2.0 was adjusted with phosphoric acid.

The flow rate was 1 ml/min. The utilized detection wavelengths were at 220 nm, 230 nm, 265 nm and 254 nm for diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine respectively, under ambient temperature.

The reference solutions were injected under the previous chromatographic conditions, the retention times were diphenhydramine 3.8 min, chlorpheniramine 2.7 min, cyproheptadine 5.5 min and fexofenadine 4.3 min. We should mention that the peak at 1.5 min in chlorpheniramine chromatogram was for the maleate (fig. 2).
Analytical method validation

Linearity

The linearity of analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration of an analyte in the sample [19].

The linearity was evaluated by linear regression analysis, which was calculated by the least square regression method. Five concentrations over the working range were prepared for each drug; this process was done three different times during three weeks (n=3). (Fig. 3) showed the regression lines of diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine with the correlation coefficients (R²) given in Table 1. All the correlation coefficients were very close to one, so the developed method was linear for analyzing the four drugs.

Range

The linearity was demonstrated in the interval (0.025-0.4 mg/ml) for diphenhydramine, (0.025-0.4 mg/ml) chlorpheniramine, (0.025-0.4 mg/ml) cyproheptadine and (0.025-0.4 mg/ml) for fexofenadine.

Fig. 2: Chromatograms of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine

Fig. 3: Linearity lines of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine
Accuracy

The accuracy of the analytical procedure: expresses the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found. For the quantitative approaches, at least nine determinations across the specified range should be obtained [19].

Three concentration levels (0.05, 0.1, and 0.2 mg/ml) have been used to study the accuracy of diphenhydramine. The results indicated that the individual recovery ranged from 97.99% to 101.68%. The recovery of diphenhydramine by the proposed method was accepted, as the mean recovery value was 99.55 between 95.0-105.0% with RSD value 1.92 not more than 5.0%.

Three concentration levels also (0.05, 0.1, and 0.2 mg/ml) have been used to study the accuracy of chlorpheniramine. The individual recovery ranged from 99.12% to 101.76 %. The recovery of chlorpheniramine by the proposed method was accepted, as the mean recovery value, 100.77 was between 95.0-105.0% with RSD value 1.43 not more than 5.0%.

Three concentration levels also (0.05, 0.1, and 0.2 mg/ml) have been used to study the accuracy of cyproheptadine. The individual recovery ranged from 98.71% to 100.68%. The recovery of cyproheptadine by the proposed method was accepted, as the mean recovery value, 99.55 was between 95.0-105.0% with RSD value 1.02 not more than 5.0%.

Finally, three concentration levels (0.05, 0.1, and 0.2 mg/ml) have been used to study the accuracy of fexofenadine. The individual recovery of fexofenadine ranged from 97.85% to 101.64%. The recovery of fexofenadine by the proposed method was accepted, as the mean recovery value, 100.25 was between 95.0-105.0% with RSD value 2.09 not more than 5.0% table 2.

Table 1: Correlation coefficients of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine

<table>
<thead>
<tr>
<th>Drug</th>
<th>Correlation coefficient (R²)</th>
<th>Equation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine</td>
<td>R² = 0.999</td>
<td>y = 20157x - 93.97</td>
</tr>
<tr>
<td>Chlorpheniramine</td>
<td>R² = 0.999</td>
<td>y = 20862x + 63.23</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>R² = 1</td>
<td>y = 15913x - 14.53</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>R² = 0.999</td>
<td>y = 1151.x + 2.463</td>
</tr>
</tbody>
</table>

**n = 3**: five concentrations over the working range, were prepared for each drug; this process was done three different times during three weeks.

Precision

The precision of an analytical procedure: expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions [19].

Intermediate Precision: The solutions 0.1 mg/ml of diphenhydramine, 0.1 mg/ml of chlorpheniramine, 0.1 mg/ml of cyproheptadine and 0.1 mg/ml of fexofenadine have been prepared at three different times, by three analysts during three weeks, each solution was injected twice (N = 6). Relative standard deviations of the calculated concentrations (RSD) were given in table 3.

The RSD of diphenhydramine was 7 %, 2.45 % for chlorpheniramine, 2.32% for cyproheptadine and 4.52% for fexofenadine (not more than 5.0 %, except for diphenhydramine which was 7 %). These results indicated that the intermediate Precision of this method was accepted for diphenhydramine, and was good for chlorpheniramine, cyproheptadine and fexofenadine.

Specificity

Specificity is the ability to assess unequivocally the analyte in the presence of components, which may be expected to be present. Typically, these might include impurities, degradants, matrix, etc [19].

The chromatograms of the reference solutions before degradation indicated no additional peaks other than those of diphenhydramine 3.8 min, chlorpheniramine 2.7 min, cyproheptadine 5.5 min and fexofenadine 4.3 min and the peak at 1.5 min in chlorpheniramine chromatogram was for the maleate (fig. 2).

In order to demonstrate the specificity of the method, reference solutions were exposed to sunlight for 60 d at room temperature. Then, they were recorded.

The chromatogram of the standing reference solution of diphenhydramine showed many additional peaks, but they were

Table 2: Mean recoveries of three concentration levels solutions of the four drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mean concentration level (0.2 mg/ml) %</th>
<th>Mean concentration level (0.1 mg/ml) %</th>
<th>Mean concentration level (0.05 mg/ml) %</th>
<th>Mean recovery % (± SD)</th>
<th>RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine</td>
<td>98.97±6.06</td>
<td>97.99±6.88</td>
<td>101.68±2.77</td>
<td>99.55±1.90</td>
<td>1.92</td>
</tr>
<tr>
<td>Chlorpheniramine</td>
<td>101.76±2.40</td>
<td>101.43±2.48</td>
<td>99.12±3.18</td>
<td>100.77±1.44</td>
<td>1.43</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>100.68±2.82</td>
<td>99.25±2.30</td>
<td>98.71±1.58</td>
<td>99.55±1.01</td>
<td>1.02</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>101.64±3.92</td>
<td>101.25±4.58</td>
<td>97.85±4.90</td>
<td>100.25±2.08</td>
<td>2.09</td>
</tr>
</tbody>
</table>

*mean±SD, n = 3.

Table 3: Relative standard deviation of the six assays of solutions of the four drugs

<table>
<thead>
<tr>
<th>N</th>
<th>Diphenhydramine (0.1 mg/ml)</th>
<th>Chlorpheniramine (0.1 mg/ml)</th>
<th>Cyproheptadine (0.1 mg/ml)</th>
<th>Fexofenadine (0.1 mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.993</td>
<td>0.102</td>
<td>0.099</td>
<td>0.107</td>
</tr>
<tr>
<td>2</td>
<td>0.094</td>
<td>0.104</td>
<td>0.098</td>
<td>0.097</td>
</tr>
<tr>
<td>3</td>
<td>0.106</td>
<td>0.104</td>
<td>0.102</td>
<td>0.098</td>
</tr>
<tr>
<td>4</td>
<td>0.106</td>
<td>0.098</td>
<td>0.102</td>
<td>0.097</td>
</tr>
<tr>
<td>5</td>
<td>0.090</td>
<td>0.097</td>
<td>0.097</td>
<td>0.099</td>
</tr>
<tr>
<td>6</td>
<td>0.097</td>
<td>0.098</td>
<td>0.098</td>
<td>0.099</td>
</tr>
<tr>
<td>Mean(±SD)</td>
<td>0.098±0.007</td>
<td>0.101±0.002</td>
<td>0.099±0.0023</td>
<td>0.101±0.0046</td>
</tr>
<tr>
<td>RSD</td>
<td>7.03</td>
<td>2.45</td>
<td>2.32</td>
<td>4.52</td>
</tr>
</tbody>
</table>

*n = 6.
well resolved from the peak of diphenhydramine with a significant difference in the retention time (fig. 4).

The chromatogram of the standing reference solution of chlorpheniramine showed other peaks in addition to the major one and the maleate peak, but they were separated from the peak of chlorpheniramine (fig. 5).

The chromatograms of the standing reference solution of cyproheptadine showed several additional peaks, appeared before the main peak with no interference (fig. 6).

The chromatograms of the standing reference solution of fexofenadine showed two additional peaks, appeared after the main peak. In this case, there was no separation between the main peak and one of the degradation peaks (fig. 7).

As a result, this method was well specific for the assay of diphenhydramine, chlorpheniramine, cyproheptadine, in the presence of their degradation products. In order to separate the fexofenadine from the degradation peak, modification of this method must be applied.

On the other hand, tests for peak homogeneity were needed by using diode array detection or mass spectrometry but we did not dispose of these techniques [19].
**Fig. 6:** Chromatogram of the standing reference solution of cyproheptadine

**Fig. 7:** Chromatogram of the standing reference solution of fexofenadine

**Fig. 8:** Chromatogram of a mixture of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine
Separation of diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine mixture

This new chromatographic method was applied literally, to separate a solution contains the four drugs together as a mixture. 254 nm was used as a common detection wavelength. The chromatogram showed a complete separation without any interference between the peaks of diphenhydramine 3.8 min, chlorpheniramine 2.8 min, cyproheptadine 5.1 min and fexofenadine 4.5 min. (fig 8).

Pharmaceutical forms assay

Finally, we applied our method to assay commercial tablets purchased from Syria, which contained the four antihistamine drugs. One formulation was analyzed for each drug. The data of tablets contents were reported in table 5. It was observed that, not all the formulations had concentrations within the specification of the USP Pharmacopeia, which recommended that tablets should contain not less than 90% and not more than 110% of the labelled amount of the active pharmaceutical ingredient for diphenhydramine, chlorpheniramine and cyproheptadine and not less than 95% and not more than 105% for fexofenadine [20]. Diphenhydramine and cyproheptadine tablets contained the active pharmaceutical ingredient, within the range 90-110% of the stated concentration with RSD not more than 5%. But chlorpheniramine tablets contained 88.42% of the active pharmaceutical ingredient, of the stated concentration with RSD 2.56% which was out of the specification. Fexofenadine tablets content was also out of specification with 90.33% of the active pharmaceutical ingredient with RSD 1.04%.

Nalluri B. N et al. result of assaying diphenhydramine tablets was 99.97±0.234 [5]. Vishal Jain et al. found 100.25% of chlorpheniramine in formulations [7]. Rajan V. Rele. Determination of fexofenadine hydrochloride in pharmaceutical dosage form By HPLC was accurate [17].

The results reported herein demonstrated that the quality of tablets of diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine sold in Syria was not totally correct.

Table 5: Results of tablets assay by the developed HPLC method

<table>
<thead>
<tr>
<th>Formulation/Name</th>
<th>Active ingredient and potency</th>
<th>Manufacturer name and country of production</th>
<th>Number of tablets</th>
<th>Drug content ±(± SD)</th>
<th>RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kartastamine</td>
<td>diphenhydramine 25 mg</td>
<td>Alishahbaa Industries (Syria)</td>
<td>20</td>
<td>95.76 ± 0.31</td>
<td>2.36</td>
</tr>
<tr>
<td>Belocamine</td>
<td>chlorpheniramine 4 mg</td>
<td>Meditech Industries (Syria)</td>
<td>20</td>
<td>88.42 ± 2.56</td>
<td>2.56</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>cyproheptadine 4 mg</td>
<td>Asia (Syria)</td>
<td>20</td>
<td>101.81 ± 0.31</td>
<td>0.31</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>fexofenadine 120 mg</td>
<td>Ibn-Alhaytham (Syria)</td>
<td>20</td>
<td>90.33 ± 1.04</td>
<td>1.04</td>
</tr>
</tbody>
</table>

*mean%±SD, n = 3.

CONCLUSION

A simple, accurate and improved ion-pair HPLC method has been developed for the determination of four antihistamine drugs diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine in pharmaceutical forms. This method was utilized to separate a mixture of the four drugs. It was applied to assay commercial formulations sold in Syria. This method could be an additional analytical technique particularly in the quality control of raw materials, active pharmaceutical ingredients and pharmaceutical formulations. The results reported herein demonstrated that the quality of the analyzed formulations of diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine in sold in Syria was not totally correct.

ACKNOWLEDGEMENT

This research work was supported by the University of Aleppo.

ABBREVIATIONS


AUTHORS CONTRIBUTIONS

The study was carried out in collaboration among all the authors. The idea was developed by Saleh Trefi, the analysis was done by Hanan Shasho, optimization was done by Amir Alhaj sakur. The manuscript was written by Saleh Trefi.

CONFLICT OF INTERESTS

There is no conflict of interest between authors

REFERENCES


